Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 23 Aug 2018
At a glance
- Drugs Docetaxel (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- Sponsors Nanology
- 14 Aug 2018 Status changed from planning to not yet recruiting.
- 30 Apr 2018 According to a NanOlogy media release, this trial is expected to begin in September 2018.
- 21 Dec 2017 New trial record